Frota ACC, et al. - Researchers sought to determine the safety as well as immune response after a booster dose of Meningococcal C conjugated (MCC) vaccine in HIV-infected children and adolescents, who had a previous low seroconversion rate after priming with MCC, at a reference HIV-care center in Rio de Janeiro. Findings demonstrated the safety of a booster dose of MCC and high seroprotection rate induced by it, even 12–18 months after priming. Administration of MCC was recommended, after the attainment of maximum virologic suppression. Findings lend support to the recommendation of 2-dose of MCC for primary immunization in HIV-infected children and adolescents with restored immune function.